E-viri
Recenzirano
-
Mandema, J W; Gibbs, M; Boyd, R A; Wada, D R; Pfister, M
Clinical pharmacology and therapeutics, December 2011, 2011-Dec, 2011-12-00, 20111201, Letnik: 90, Številka: 6Journal Article
High development cost, low development success, cost‐disciplined health‐care policies, and intense competition demand an efficient drug development process. New compounds need to bring value to patients by being safe, efficacious, and cost‐effective as compared with existing treatment options. Model‐based meta‐analysis (MBMA) facilitates integration and utilization of summary‐level efficacy and safety data, providing a quantitative framework for comparative efficacy and safety assessment.1,2 This Commentary discusses the application and limitations of MBMA in drug development. Clinical Pharmacology & Therapeutics (2011) 90 6, 766–769. doi:10.1038/clpt.2011.242
